Galectin Therapeutics Inc’s filing revealed that its Director FREEMAN KEVIN D acquired Company’s shares for reported $7450.0 on Apr 22 ’24. In the deal valued at $2.98 per share,2,500 shares were bought. As a result of this transaction, FREEMAN KEVIN D now holds 25,969 shares worth roughly $87775.22.
Then, ELDRED KARY bought 500 shares, generating $893 in total proceeds. Upon buying the shares at $1.79, the Director now owns 49,313 shares.
Before that, ELDRED KARY bought 1,598 shares. Galectin Therapeutics Inc shares valued at $2,854 were divested by the Director at a price of $1.79 per share. As a result of the transaction, ELDRED KARY now holds 48,813 shares, worth roughly $0.16 million.
H.C. Wainwright reiterated its Galectin Therapeutics Inc [GALT] rating to a Buy in a research note published on August 13, 2020; the price target was $12. A number of analysts have revised their coverage, including B. Riley FBR’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering GALT and reiterated its “Buy” recommendation on December 07, 2017. H.C. Wainwright maintained its rating on November 28, 2017. It rated GALT as “a Buy”.
Price Performance Review of GALT
On Tuesday, Galectin Therapeutics Inc [NASDAQ:GALT] saw its stock jump 10.46% to $3.38. Over the last five days, the stock has lost -0.59%. Galectin Therapeutics Inc shares have risen nearly 103.61% since the year began. Nevertheless, the stocks have risen 76.04% over the past one year. While a 52-week high of $4.27 was reached on 04/12/24, a 52-week low of $1.28 was recorded on 02/07/24. SMA at 50 days reached $2.49, while 200 days put it at $1.97. A total of 0.24 million shares were traded, compared to the trading of 0.31 million shares in the previous session.
Levels Of Support And Resistance For GALT Stock
The 24-hour chart illustrates a support level at 3.06, which if violated will result in even more drops to 2.75. On the upside, there is a resistance level at 3.62. A further resistance level may holdings at 3.87. The Relative Strength Index (RSI) on the 14-day chart is 57.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.32, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.57%. Stochastics %K at 44.13% indicates the stock is a holding.
The most recent change occurred on October 19, 2017 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating .
